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Abstract 
Epigenetic mechanisms are fundamental for shaping the activity of the central nervous 
system (CNS). Methyl-CpG binding protein 2 (MECP2) acts as a bridge between 
methylated DNA and transcriptional effectors responsible for differentiation programs in 
neurons. The importance of MECP2 dosage in CNS is evident in Rett Syndrome and 
MECP2 duplication syndrome, which are neurodevelopmental diseases caused by loss-of-
function mutations or duplication of the MECP2 gene, respectively. Although many studies 
have been performed on Rett syndrome models, little is known about the effects of an 
increase in MECP2 dosage. Herein, we demonstrate that MECP2 overexpression affects 
neural tube formation, leading to a decrease in neuroblast proliferation in the neural tube 
ventricular zone. Furthermore, an increase in MECP2 dose provokes premature 
differentiation of neural precursors accompanied by greater cell death, resulting in a loss of 
neuronal populations. Overall, our data indicate that correct MECP2 expression levels are 
required for proper nervous system development. 
Introduction 
During development, mitotically active precursors located in the neuroepithelium give rise 
to specialized neuronal and glial cells that define the adult nervous system. To maintain the 
brain's complexity, neurons originating from the neural tube undergo mitotic quiescence. 
Therefore, neuronal differentiation encompasses an elaborate developmental program in 
which neurogenic and antiproliferative signals work together to guarantee the differentiated 
state. This developmental step is mediated by genetic and epigenetic factors. Among the 
latter, chromatin remodelers (Clapier and Cairns, 2009), histone variants (Kamakaka and 
Biggins, 2005), histone post-translational modifications (Kouzarides, 2007) and DNA 
methylation (Miranda and Jones, 2007) are strongly involved in regulating the proliferation 
and differentiation of neural precursor cells. The importance of this regulation is 
highlighted by several neurological disorders caused by mutations in epigenetic genes, such 
as Rett syndrome (RTT), alpha thalassemia/mental retardation X-linked syndrome, 
Rubinstein–Taybi syndrome and Coffin–Lowry syndrome (Urdinguio et al., 2009). 
Among the epigenetic regulators of the brain, methyl-CpG-binding proteins are responsible 
for reading the methylation code of DNA and therefore, for regulating gene transcription 
(Klose and Bird, 2006). In fact, a mutation in the best-known protein of this family, 
MECP2 (methyl-CpG binding protein 2), is responsible for RTT (Amir et al., 1999). 
MECP2 is a basic nuclear protein that acts mainly as a transcriptional repressor, 
preferentially binding to methylated DNA sequences (Klose et al., 2005 and Lewis et al., 
1992). Although MECP2 is widely expressed, MECP2 levels are highest in the brain, 
principally in mature postmigratory neurons (Jung et al., 2003). MECP2 protein levels are 
low during embryogenesis and increase progressively during the postnatal period of 
neuronal maturation (Balmer et al., 2003 and Cohen et al., 2003). In addition to its 
necessary role in mature neuronal and glial cells, MECP2 has been implicated in neuronal 
specification during early embryogenesis in several species (Coverdale et al., 
2004 and Stancheva et al., 2003). Moreover, MECP2 has been shown to promote neuronal 
differentiation of neural stem cells while repressing astrocyte differentiation (Tsujimura et 
al., 2009). 
The striking finding that MECP2 nucleotide mutations or duplications cause Rett syndrome 
or MECP2 duplication syndrome, respectively, suggests that careful regulation of this gene 
is necessary for correct brain development and function, as both overexpression and 
reduced expression are associated with neurodevelopmental disorders (Collins et al., 
2004 and del Gaudio et al., 2006). Intriguingly, a loss of MECP2 function and an increase 
in MECP2 dosage lead to clinically similar neurological disorders (Van Esch et al., 2005). 
However, although many studies have been performed on MECP2 loss-of-function models, 
little is known about the biological consequences of MECP2 overexpression in either the 
adult or developing brain. 
Using a well-known developmental model, the chick embryo neural tube, we sought to 
investigate the effects of human MECP2 overexpression on the proliferating progenitor 
cells of neurons and glia. Here, we show that MECP2 dosage is fundamental for proper 
neural tube development and demonstrate that MECP2 overexpression provokes premature 
differentiation of proliferating progenitor cells. This ectopic differentiation leads to cell-
cycle exit and cell death, ultimately resulting in decreased neuronal populations. 
Materials and methods 
Plasmids 
The human MECP2_e1 full-length coding sequence was cloned into pCIG vector (Megason 
and McMahon, 2002). The vector comprises CMV enhancer and beta-actin promoter, 
followed by multiple cloning sites, internal ribosomal entry site (IRES) and a nuclear-
localized green fluorescent protein (GFP). 
Antibodies 
The following primary antibodies were used: anti-MECP2 (Diagenode, custom); anti-BrdU 
(DSHB, G3G4); anti-phosphoH3S10 (Millipore, 05–806); anti-neural β -tubulin III (Tuj1) 
(R&D systems, MAB1195); anti HuC/D (Life Technologies, A-21271); anti-N-cadherin 
(R&D systems, AF6426); anti-active Caspase 3 (BD pharmingen, 559565); anti-active 
Caspase 8 (Millipore, MAB10754) and anti-β-actin-peroxidase (Sigma, A3854) 
Chick in ovo electroporation 
Eggs from White-Leghorn chickens were incubated at 38.5 °C and 70% humidity. Embryos 
were staged according to Hamburger and Hamilton (HH) (Hamburger and Hamilton, 1992). 
Chick embryos were electroporated with purified plasmid DNA at 2–3 μg/μl in H2O with 
50 ng/ml of Fast Green. Plasmid DNA was injected into the lumen of HH10 neural tubes, 
electrodes were placed at both sides of the neural tube and finally, the embryos were 
electroporated by an IntracelDual Pulse (TSS-100) delivering five 50 ms square pulses of 
20–25 V. 
mRNA extraction and RT-PCR 
RNA was extracted with a Trizol reagent (Invitrogen) from dissected neural tubes 
according to the manufacturer's protocol. Single-stranded cDNA was synthesized with 
Thermoscript reverse-transcriptase and random hexamers (Life Technologies), and then 
subjected to PCR with the following primers: cMECP2, forward 5′-
GGACCAGGAAGCTCAAACAGC-3′ and reverse 5′-TTGGGGCTCTTGGCTTTCTTG-
3′; Gapdh, forward 5′-CTGAATGGGAAGCTTACTG-3′ and reverse, 5′-
CATCATACTTGGCTGGTTTC-3′. 
 
Western blotting 
Neural tubes were dissected from several embryos at the same stage, pooled together and 
total protein was extracted with a Laemmli buffer. Equal amounts of protein (20 μg) were 
boiled for 10 min and β-mercaptoethanol was added to a 3% final concentration. Samples 
were then separated by electrophoresis on 10% SDS-PAGE gels, and transferred to 
nitrocellulose membranes. Membranes were blocked in 5% skim milk powder in PBS plus 
0,1% Tween 20 for 1 h at room temperature and then incubated overnight at 4 °C with 
primary antibodies. For MECP2 (1:2000) antibody, an anti-rabbit HRP-conjugated 
secondary antibody (1:10,000) was used. Finally, complexes on the membrane were 
visualized using an ECL detection kit (GE Healthcare Life Sciences). 
BrdU incorporation 
Bromodeoxyuridine (BrdU, 0.5 μg/μl) was injected into the chick embryo neural tube 
lumen 30 min before fixation. Before anti-BrdU antibody incubation (which was performed 
as described below), the sections were treated with HCl 2 N for 30 min and washed with 
NaBorate 0.1 M (pH 8.5). 
Indirect immunofluorescence 
The collected brachial regions from embryos were fixed for 2 h at 4 °C in 4% 
paraformaldehyde, rinsed with PBS, soaked in a PBS 30% sucrose solution and embedded 
in either OCT or agarose for sectioning in a Leica Cryostat (CM 1900) or a Vibratome 
(VT1000). The sections were blocked at room temperature for at least 1 h in 1% BSA (in 
PBS with 0.1% Triton X-100) before overnight incubation with primary antibodies at 4 °C. 
The sections were then incubated for 1.5 h at room temperature with Alexa-conjugated goat 
secondary IgG antibodies (Life Technologies) and 0.1 ng/μl DAPI (Sigma). Images were 
captured on a Leica SP5 confocal microscope using a 40 × oil-immersion objective and 
processed using a Fiji software. MECP2 intensity was quantified using the Fiji software as 
the following: each side of the neural tube (MECP2 EP and control) was selected as a 
region of interest (ROI) and the total intensity of all pixels for each ROI was calculated and 
compared. 
Statistical analysis 
Quantitative data were expressed as mean and standard error (s.e.). Significant differences 
between groups were tested by Student's t-test. 
Results 
Chicken MECP2 is expressed ubiquitously in the developing spinal cord 
MECP2 is present in all vertebrates and is highly conserved among mammals, while 
divergence between mammalian and amphibian or fish MeCP2 more extensive. However, 
the alignment of chicken MECP2 with mouse and human MECP2 shows that the protein is 
highly conserved throughout species as diverse as humans and chickens. Although 
cMECP2 mRNA and protein are only partially annotated, a large part of the sequence is 
highly similar to human MECP2. Particularly striking is the 96.8% sequence identity in a 
125-amino-acid region. Significantly, the conserved region includes the methyl-CpG 
binding domain (MBD) (Weitzel et al., 1997) (Fig. 1a). The high degree of conservation 
compares well with the characterization of the MBD as an essential element for binding of 
MECP2 to heterochromatin as well as unmethylated four-way DNA junctions (Galvão and 
Thomas, 2005 and Nan et al., 1996). Hence, we wondered whether cMECP2 (previously 
known as ARBP) is expressed in the chicken embryo across different developmental stages. 
RT-PCR analysis of HH10, 20, 23 and 26 revealed that cMECP2 is indeed expressed in 
chick embryo ( Fig. 1b) with greater expression seen at the HH20 stage. Since transcript 
presence does not always correlate with protein levels, we checked cMECP2 protein by 
western blot. Fig. 1c shows that cMECP2 is expressed at every tested developmental stage. 
Although in HH10 chick embryos the neural tube is formed mainly by the ventricular zone 
(VZ)—an epithelium composed entirely of mitotically active, multipotent neural precursor 
cells—from HH14 to 15 some of these neuroblasts exit the cell cycle and migrate laterally 
from the ventricular zone to the mantle zone (MZ), which is formed exclusively by post-
mitotic, differentiating neurons and glia ( Fig. 1d). Therefore, we wondered whether the 
MECP2 expression was restricted to the differentiating neurons or was global. To address 
this issue, we collected brachial sections of HH25 embryos and stained them with an anti-
MECP2 antibody that recognizes the region shown in Fig. 1e. The chicken MECP2 partial 
annotated region shows high homology with the aminoacidic region of the mammalian 
MECP2 counterpart, thus, expecting that the antibody recognizes chicken MECP2 
specifically ( Weitzel et al., 1997). The results illustrate high expression of cMECP2 in 
ventral and in more dorsal ventricular cells as well as in mantle cells ( Fig. 1f, top panel). 
Thus, MECP2 is present both in differentiated neurons and in neural progenitors. 
Moreover, we found that cMECP2 localizes in the nucleus, as staining of MECP2 overlaps 
with DAPI ( Fig. 1f, bottom panel). 
MECP2 overexpression reduces neuroblast proliferation 
To investigate the role of a protein, lack and gain-of function studies are needed. The pCIG 
plasmid has been used in many gain-of-function studies to obtain new insights on genes 
function relevant for development, such as hJag1 (Neves et al., 2011), Wnt (Megason and 
McMahon, 2002), EZH2 (Akizu et al., 2010) and FGF (Martínez-Morales et al., 2011) 
among others, whose expression reached high levels when electroporated in ovo. Although 
different shRNA of the cMECP2 annotated region have been electroporated in chicken 
embryo, none of them worked (data not shown). 
Humans and mice have two protein isoforms produced by the alternative splicing of the 
MECP2/MECP2 gene with the MECP2E1 and E2 isoforms, differing only in their N-
terminal sequences (Kriaucionis and Bird, 2004). It is known that MECP2E1-specific 
mutations alone are able to cause RTT (Gianakopoulos et al., 2012) and MECP2E1 
displays 10 times more expression than E2 (Dragich et al., 2007). In addition, a recent 
study reported the differential distribution of MeCP2E1 within various brain regions in 
mice (Zachariah et al., 2012). With the aim to investigate the presence of different MECP2 
isoforms in chicken we used a RT-PCR approach. Our exon-specific RT-PCR experiments 
based on the protein alignment between human and chicken and designed to amplify the 
sequence between Exons 1 and 3, failed to detect a second cMECP2 transcript (data not 
shown). 
In order to analyze the effects of increased MECP2 dosage on the developing neural tube, 
we cloned MECP2_E1 full-length into a pCIG vector under the control of a CMV 
promoter. The additional expression of a nuclear-localized GFP from an internal ribosome 
entry site (IRES) enabled easy identification of transfected cells. In ovo injection of 
MECP2 expression plasmid into HH10 embryos and subsequent electroporation led to 
efficient and unilateral expression of this protein in the neural tube as it is shown in Fig. 2a, 
where the GFP channel colocalizes with the MECP2 red channel. Noteworthy, the pattern 
of nuclear localization of the endogenous protein is maintained upon MECP2 
overexpression and the intensity of MECP2 signal is increased. Quantification of MECP2 
intensity in electroporated (EP) neural tube compared with pCIG EP reveals an average of 
45-fold more MECP2 in the electroporated region (Fig. 2a, graph). Although at 24 hours 
post-electroporation (PE) the neural tubes did not show any evidence of altered phenotypes, 
at 48 (data not shown) and 72 hours PE the thickness and the structure of electroporated 
neural tubes were highly affected, compared to the non-electroporated side or to the empty 
vector. The most striking feature associated with the overexpression of MECP2 was the 
vastly reduced area occupied by the MZ, whose strong phenotype is appreciated in Figs. 2b, 
c, 3a, b and c. 
To elucidate the mechanisms by which MECP2 overexpression so profoundly alters neural 
tube organization, we examined the proliferation rate of electroporated neural tubes. We 
took embryos at 72 h PE and processed them for bromodeoxyuridine (BrdU) staining, 
showing that MECP2 overexpression leads to an overall decrease in the number of 
proliferating BrdU positive cells (Fig. 2b). Noteworthy, the most affected part corresponds 
with higher levels of GFP (compare zoom squares of pCIG EP and MECP2 EP panels in 
Fig. 2b). In addition, in EP pCIG, GFP-labeled cells accumulated at the mantle zone due to 
the normal migration accompanying neuronal differentiation, while in EP MECP2 
electroporated cells gathered mainly in the VZ, therefore making not possible to assess 
colocalization between GFP and BrdU. In order to quantify BrdU incorporation, BrdU 
labeled cells in control (pCIG) and MECP2 EP neural tubes were normalized with the total 
number of BrdU-positive cells in the respective non-EP side (graph of Fig. 2b). Results 
clearly indicate a reduction around 20% in BrdU levels as a result of MECP2 
overexpression. We then wondered whether MECP2 overexpression affected also the levels 
of H3S10 phosphorylation, a histone mark that correlates with mitotically active cell 
populations. The H3S10p marker highlighted a mislocalization of actively dividing cells 
that normally reside close to the lumen. Again, higher levels of GFP coincide with 
disruption of H3S10p pattern (compare zoom square of pCIG EP and MECP2 EP panels in 
Fig. 2c). Quantification of anti-H3S10p immunostaining also showed that MECP2-
electroporated neural tubes has a 20% decrease in the amount of mitotic cells than did the 
control neural tubes (Fig. 2c, graph). Collectively, these data emphasize the importance of 
proper spatial–temporal MECP2 expression for ensuring correct proliferation of progenitor 
cells residing in the ventricular zone of the neural tube. 
MECP2 overexpression induces ectopic localization of differentiated neurons 
Given that a role for MECP2 in promoting neuronal differentiation of neural precursor cells 
has been proposed (Stancheva et al., 2003 and Tsujimura et al., 2009), we wondered 
whether the reduced proliferation of neural progenitor cells that we observed stemmed from 
premature induction of neurogenesis. To investigate this possibility, we took MECP2-
electroporated neural tubes at 72 h PE, and then stained them with neural β-tubulin III 
(Tuj1), which is one of the earliest markers of neuronal commitment in primitive 
neuroepithelium. Fig. 3a show that MECP2 overexpression provokes a clear decrease in the 
amounts of differentiated neuronal population located at the mantle zone (compare zoom 
squares of pCIG control and MECP2 EP panels). Additionally, the same images of Tuj1 
staining also show an ectopic localization of differentiated neurons in the MECP2-
electroporated neural tubes. To confirm the phenotype caused by MECP2 overexpression, 
we immunostained with another marker, HuC/D, an RNA-binding protein specific to 
neuronal lineage. Again, when comparing MECP2 EP neural tubes with controls, depletion 
of differentiated cells is observed in MZ of MECP2 EP neural tubes (Fig. 3b, pCIG and 
MECP2 panels). This phenotype unequivocally shows an aberrant differentiation pattern 
for cells overexpressing MECP2, as it can be inferred by the presence of both GFP and 
Tuj1 in ectopically differentiated cells. Due to the non-nuclear localization of Tuj1 and 
HuC/D it has not been possible to quantify labeled cells of these markers. However, 
quantification of such qualitative markers was not necessary given that the difference in the 
level of staining of the mantle zone was striking, as well as it was the presence of Tuj1-
stained cells in the VZ, which is normally populated by proliferating cells. 
Since Tuj1 staining was found in the ventricular zone, we decided to check for 
neuroepithelial polarity markers, such as the cadherin family of proteins. In particular, the 
pattern of N-cadherin (Cdh2), a transmembrane protein that mediates homophilic adhesion 
at the cell junctions, was analyzed by immunostaining in the MECP2-electroporated neural 
tubes (at 72 h PE). The results clearly demonstrate that MECP2 overexpression disrupts the 
N-cadherin expression pattern along the lamina of the neural tube (Fig. 3c, compare zoom 
squares of control and MECP2 EP panels). This indicates that an increase in MECP2 
dosage leads to a decrease in neuroepithelial polarity markers. These results suggest that, in 
addition to exiting the cell cycle and suffering from compromised polarity, MECP2-
overexpressing neural precursor cells do not reach terminal differentiation, as can be 
inferred by reduced number of differentiating neurons in the MZ (Figs. 3a, c MECP2 
panel). 
MECP2 overexpression induces cell death 
The observations that at 72 h PE the number of Tuj1 labeled cells in MECP2-electroporated 
neural tubes is vastly reduced, led us to analyze the rate of apoptosis before the onset of the 
altered phenotype. To this end, we determined the cellular levels of active Caspase-3 and 
− 8, two well-known serine proteases that are activated during the early-intermediate stages 
of apoptosis (reviewed in Parrish et al., 2013). Caspase-8 is classified as an initiator caspase 
and it is one of the earliest signals in the cascade, while Caspase-3 act downstream and can 
be cleaved, and therefore activated, by Caspase-8. Control pCIG EP neural tubes show very 
low levels of Caspase-3 and − 8 labeled cells as expected (Figs. 4a and b pCIG EP panel, 
graph 4c and 4d). However, the number of Caspase-3 and Caspase-8 labeled cells in 
MECP2 EP compared with pCIG EP neural tubes is significantly higher both at 24 and 48 h 
PE (Figs. 4a and b MECP2 EP panel, graph 4c and 4d). To confirm these data we 
quantified cells undergoing cell death by counting Dapi-positive nuclei showing the 
characteristic condensed morphology. Fig. 4e shows an increase of pyknotic cells in 
MECP2 EP, both at 24 and 48 h PE compared with pCIG EP neural tubes. These results 
clearly indicate the presence of apoptotic cells upon MECP2 electroporation and can 
explain the aberrant phenotype. 
Discussion 
To analyze the role of MECP2 in neurogenesis we have used a chicken model, however, we 
first checked whether our model was suitable for this purpose. First, expression of both 
cMECP2 transcript and protein has been detected in a wide window of developmental 
stages. Then, we have found that chicken MECP2 is functionally analogous to its 
mammalian counterpart since its nuclear localization and the conservation of the region 
encompassing the methyl-CpG binding domain between human and chicken. 
Our data also indicate that MECP2 overexpression causes neuroblasts to slow down 
proliferation, and that most of these neuroblasts die before they can reach terminal 
differentiation (Fig. 4f). Ectopic localization of differentiated neurons and reduced levels of 
polarity markers indicate that overexpression of MECP2 alone does not control the changes 
in polarity and migration that accompany neurogenesis. Neural cells die as a consequence 
of MECP2 overexpression, probably because they lack the additional spatial–temporal 
signals necessary for proper progression of neurogenesis. These results are in line with the 
lack of function studies from other models (Stancheva et al., 2003), indicating that the 
consequences of MECP2 overexpression do not represent toxic effects but specific ones. 
Tsujimura et al. (2009) showed that MeCP2 overexpression in neural precursor cells 
(NPCs) promotes neuronal differentiation in adult mice. This work was based on the 
injection of embryo-derived NPCs in the brain or spinal cord of adult mice. We provided a 
more reliable study in which MECP2 ectopic expression has been induced in the chick 
neural tube without the need to deliver exogenous cells to the embryos. Our results are 
consistent with previous studies, which reported abnormally high levels of cell death in 
different in vitro systems overexpressing MECP2, relative to wild-type cells (Bracaglia et 
al., 2009 and Dastidar et al., 2012). Bracaglia et al. also reported that this pro-apoptotic 
effect disappears when the Rett syndrome-associated MECP2-R106W mutant, which is 
unable to bind to methylated DNA, is expressed—thereby implying that the MBD domain 
is essential for MECP2-induced apoptosis. 
It is remarkable that Xenopus laevis MeCP2 was shown to regulate the number of neural 
precursor cells in the differentiating neuroectoderm of early Xenopus embryos ( Stancheva 
et al., 2003). In the absence of MeCP2 protein, the expression of Xenopus Hairy2a (a 
member of the Hes family of proteins, which are regulated by the Notch/Delta signaling 
pathway) was enhanced in embryos, which resulted in a lower number of differentiated 
neurons. Our results, together with the aforementioned study, highlight the importance of 
MECP2 dosage, as both knock-out and overexpression of this protein results in a reduced 
number of differentiated neurons. In our case, reduction in total number of cells is not due 
only to apoptosis but in addition there is a proliferation problem. 
Interestingly, our phenotype resembles the one produced by the genetic ablation of Notch1 
(de la Pompa et al., 1997). Loss of Notch signaling results in premature onset of 
neurogenesis by neuroepithelial cells of the midbrain–hindbrain region of the neural tube. 
Notch1-deficient cells do not complete differentiation but instead are eliminated by 
apoptosis, resulting in a reduced number of neurons in the adult cerebellum (Lütolf et al., 
2002). 
The molecular mechanism responsible of this phenotype can be explained by the relevant 
interactions between MECP2 and other proteins. For example, the MECP2-associated 
kinase HIPK2 has been shown to regulate cell growth and apoptosis, both in vivo and in 
vitro (Bracaglia et al., 2009). In addition, MECP2 interacts with many co-factors crucial for 
both proliferation and differentiation, such as HDAC2 (MacDonald et al., 2010) and 
NCOR/SMRT (Ebert et al., 2013). 
This is the first study that investigates the consequences of MECP2 gain-of-function in the 
nervous system of an in-vivo model in the early stages of development. In particular, we 
introduce the novel idea that high expression of MECP2 in mitotic cells leads to anti-
proliferative and apoptotic effects. Several cases of increased MECP2 copy number have 
been reported in male patients with progressive neurodevelopmental delay phenotype (Friez 
et al., 2006, Lugtenberg et al., 2006, Meins et al., 2005 and Van Esch et al., 2005). 
Interestingly, a male patient with triplication of the MECP2 locus was described to have an 
even worse early-onset neurological phenotype at 3 months of age (del Gaudio et al., 2006), 
suggesting that the severity of an MECP2 overexpression phenotype is proportional to the 
copy number increase. In order to reinforce this hypothesis, researchers have studied a 
mouse model expressing seven times the wild-type levels of MeCP2 protein, reporting that 
it died by 3 weeks of age (Collins et al., 2004). Although the levels of MECP2 expression 
induced in the chicken neural tubes that we have described in the present study are not fully 
representative of the physiological situation in patients with MECP2-related disorders, our 
results are in line with lack and gain of function studies that elucidate the importance of 
correct gene dosage in neuronal development and disorders. 
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 Figure Legends 
 Figure1 
 cMECP2 is ubiquitously expressed in the developing spinal cord. (a) Protein 
sequences of chicken (Accession no. CAA74577), human (NP_001104262) and mouse 
(NP_001075448) MECP2 were aligned. The region inside the black box shows that the 
human sequence and the chicken sequence share 96.8% identity. MBD (yellow) and TRD 
(red) domains are highlighted. (b) RT-PCR on HH10, 20, 23 and 26 neural tube RNA 
extracts. Minus reverse transcriptase samples (− RT) are shown on the right. (c) 
Immunoblot on HH10, 20, 23 and 26 neural tubes. (d) Scheme showing the neural tube 
organization at HH10 and 25. (e) The cMeCP2 fragment is partly conserved with the 
human peptide recognized by the antibody. (f) HH25 embryos were dissected and brachial 
sections were stained for MECP2 (red) and DAPI (blue). 
 
 Figure 2  
 Neuroblast proliferation is reduced upon MECP2 overexpression. HH10 embryos 
were electroporated with MECP2 or the empty vector in a bicistronic plasmid containing 
EGFP. All sections were taken from the brachial region. (a) MECP2 immunostaining (red) 
of embryos at 72 h PE. The graph shows MECP2 area intensity of MECP2 EP neural tubes 
relative to the empty vector (pCIG). Intensities were quantified by a Fiji software. Data 
shows mean of n = 3 sections (from 3 different embryos). Error bars indicate s.e. *p < 0.05. 
(b) BrdU immunostaining (red) of 72 h PE embryos. The magnified red boxes show the 
most affected regions. The graph shows the number of BrdU positive cells found in 
MECP2 EP neural tubes relative to pCIG. Data show the mean of n = 9 sections (from three 
embryos). Error bars indicate s.e. ***p < 0.001. (c) H3S10p immunostaining (blue). The 
magnified red boxes show the most affected regions. The graph shows the number of 
H3S10p positive cells found in MECP2 EP neural tubes relative to pCIG. Data for pCIG 
show the mean of n = 8 sections (from three embryos), for MECP2 n = 12 sections (from 
two embryos). Error bars indicate s.e. **p < 0.01.  
  
 Figure 3  
 MECP2 overexpression provokes ectopic localization of differentiated neurons. a 
Tuj1 immunostaining (gray, upper panel) of embryos at 72 h PE. GFP is shown in the 
lower panel. For MECP2 EP, two embryos are shown. The magnified red box shows 
ectopically differentiating neurons. b HuC/D immunostaining (gray, upper panel). For 
MECP2 EP, two embryos are shown. c N-cadherin immunostaining (gray, upper panel). 
The magnified red box shows disruption of the N-cadherin pattern by MECP2. 
  
 Figure 4  
 MECP2 overexpression induces cell death. (a–b) HH10 embryos were 
electroporated with MECP2 or empty vector. Embryonic sections (at 24 and 48 h PE) from 
brachial region were immunostained for Caspase 8 (a) (gray, lower panel) and Caspase 3 
(b) (gray, lower panel). The red boxes in the MECP2 EP highlight the Caspase-positive 
spots. c–d The graphs show the number of Caspase 8 (c) and Caspase 3 (d) positive cells in 
MECP2 EP neural tubes relative to pCIG EP at 24 and 48 h PE (pCIG 24 and 48 h n = 12 
sections from 6 embryos; MECP2 24 h n = 21 from 10 embryos; MECP2 48 h n = 13 from 
6 embryos). Error bars indicate s.e. *p < 0.05; **p < 0.01; ***p < 0.001. (e) Quantification 
of cells showing pyknotic features in neural tubes at 24 and 48 h PE (pCIG 24 and 48 h 
n = 12 sections from 6 embryos; MECP2 24 h n = 21 from 10 embryos; MECP2 48 h 
n = 13 from 6 embryos). Error bars indicate s.e. **p < 0.01; ***p < 0.001. (f) Model for 
MECP2 overexpression consequences in neural tube. 
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